One of CARLS reply to my question about 2 weeks ago28 Apr 2021 11:18
Well, I cannot comment on Directors buying or selling shares, not least because I don’t have any insight, knowledge or understanding.
However, the epidemiological science around this is very clear, as it has been from the beginning. This virus will be with the world for the foreseeable future, and until such times as EVERY country has it under control, with significant levels of vaccination, the risks associated with variants, reinfection and waning immunity are too high to ignore. The first wave of expensive disposable tests undertaken willy-nilly, will need to be replaced with a sustainable testing infrastructure that is scaleable, and economic for commercial enterprises who will have to incorporate the costs into their product offering. It’s not realistic to have tests that cost more than the aircraft seats that airlines will be trying to safely fill.
Importantly, a fast test can be a cheap test because of the high throughput. Up to now, the model has been the “hospital” type test and associated cost. I envision our test to resemble the “supermarket” model, where low cost testing allows people to routinely test, at relatively high frequency.
Critically, the effect of this pandemic has been to make globalists aware of the vulnerabilities associated with high levels of global trade. High levels of vigilance - and associated testing infrastructure, are here to stay.
The science has progressed very well indeed, and I will be talking about this a bit more over the next little while
Sign In
Follow the stocks
